CRBU
Caribou Biosciences IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$164.64M
P/E Ratio
—
EPS
$-1.42
Beta
2.33
52W High
$3.54
52W Low
$1.04
50-Day MA
$2.05
200-Day MA
$1.95
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Caribou Biosciences Inc
Caribou Biosciences Inc. is a pioneering biotechnology firm specializing in cutting-edge genome editing technologies, particularly through its proprietary CRISPR platform. With a robust and diversified pipeline of innovative product candidates aimed at tackling urgent unmet medical needs in genetic disorders and oncology, the company is well-positioned to lead advancements in precision medicine. Leveraging strategic partnerships and a commitment to transformative research, Caribou aims to redefine treatment paradigms and significantly improve patient outcomes, establishing itself as a formidable entity in the biopharmaceutical sector.
Fundamentals
| Revenue (TTM) | $11.20M |
| Gross Profit (TTM) | $-81.40M |
| EBITDA | $-114.16M |
| Operating Margin | -1096.00% |
| Return on Equity | -83.50% |
| Return on Assets | -34.70% |
| Revenue/Share (TTM) | $0.12 |
| Book Value | $1.05 |
| Price-to-Book | 1.61 |
| Price-to-Sales (TTM) | 14.70 |
| EV/Revenue | 6.6 |
| EV/EBITDA | -36.94 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1.90% |
| Shares Outstanding | $99.18M |
| Float | $94.81M |
| % Insiders | 8.91% |
| % Institutions | 37.90% |
Historical Volatility
HV 10-Day
85.08%
HV 20-Day
80.90%
HV 30-Day
72.09%
HV 60-Day
70.31%
HV Rank
35.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($12.00 target)
1
Strong Buy6
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026